Skip to main content

Advertisement

Table 6 Basic results. Disaggregated costs (€) of the options compared

From: Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist

Years since initiation PSM PCpc Hpc Hvp Dabi
Total AC Compl Total AC Compl Total AC Compl Total AC Compl Total AC Compl
Spanish National Health Service Perspective
1 1066 659 407 820 259 562 967 409 558 884 324 560 1454 1058 396
5 3692 1373 2319 3846 644 3202 4296 1124 3173 4148 969 3179 5757 3631 2125
10 6217 1747 4470 6707 800 5907 7269 1415 5854 7096 1231 5865 9026 4981 4045
Lifetime 9118 1938 7179 9668 858 8810 10,266 1521 8745 10,084 1327 8756 12,198 5672 6526
Societal perspective
1 1228 826 402 1081 526 555 1640 1100 540 1557 1015 542 1454 1058 396
5 4059 1755 2305 4648 1501 3147 6367 3339 3029 6221 3184 3037 5757 3631 2125
10 6691 2241 4450 7706 1898 5808 9846 4250 5596 9675 4067 5609 9026 4981 4045
Lifetime 9653 2491 7162 10,728 2043 8685 12,999 4583 8416 12,821 4389 8432 12,198 5672 6526
  1. AC Anticoagulation including INR monitoring plus drug cost; PSM Patient self-management; PCpc Primary care with portable coagulometer; Hpc Hospital care with portable coagulometer; Hvp Hospital care with venipuncture; Dabi Dabigatran; Compl complications